Zoetis Inc. (ZTS) Income Statement

NYSE: ZTSRevenue, profits, margins and EPS over 10 years.

ZTS 2025 at a glance

Fiscal year ended December 31, 2025 · U.S. dollars
Revenue+2.3%
$9.47B
2025 · hover or tap a bar for each year
2016: $4.89B (+2.6%)2017: $5.31B (+8.6%)2018: $5.83B (+9.8%)2019: $6.26B (+7.5%)2020: $6.67B (+6.6%)2021: $7.78B (+16.5%)2022: $8.08B (+3.9%)2023: $8.54B (+5.7%)2024: $9.26B (+8.3%)2025: $9.47B (+2.3%)
20162025
Gross profit+4.3%
$6.67B
2025 · hover or tap a bar for each year
2016: $3.14B (+5.9%)2017: $3.44B (+9.5%)2018: $3.80B (+10.3%)2019: $4.11B (+8.3%)2020: $4.46B (+8.4%)2021: $5.31B (+19.2%)2022: $5.48B (+3.1%)2023: $5.83B (+6.5%)2024: $6.40B (+9.6%)2025: $6.67B (+4.3%)
20162025
Operating income+6.0%
$3.60B
2025 · hover or tap a bar for each year
2016: $1.40B (+29.8%)2017: $1.73B (+23.0%)2018: $1.88B (+8.9%)2019: $2.02B (+7.3%)2020: $2.27B (+12.4%)2021: $2.80B (+23.5%)2022: $2.93B (+4.5%)2023: $3.07B (+4.8%)2024: $3.39B (+10.5%)2025: $3.60B (+6.0%)
20162025
Net income+7.5%
$2.67B
2025 · hover or tap a bar for each year
2016: $821.0M (+142.2%)2017: $864.0M (+5.2%)2018: $1.43B (+65.3%)2019: $1.50B (+5.0%)2020: $1.64B (+9.2%)2021: $2.04B (+24.4%)2022: $2.11B (+3.8%)2023: $2.34B (+10.9%)2024: $2.49B (+6.1%)2025: $2.67B (+7.5%)
20162025
EPS (diluted)+8.4%
$6.42
2025 · hover or tap a bar for each year
2016: $1.96 (+10.7%)2017: $2.40 (+22.4%)2018: $3.14 (+30.8%)2019: $3.64 (+15.9%)2020: $3.85 (+5.8%)2021: $4.70 (+22.1%)2022: $4.88 (+3.8%)2023: $5.32 (+9.0%)2024: $5.92 (+11.3%)2025: $6.42 (+8.4%)
20162025
Net profit margin+1.4 pts
28.2%
2025 · hover or tap a point for each year
2016: 16.8% (+9.7 pts)2017: 16.3% (−0.5 pts)2018: 24.5% (+8.2 pts)2019: 24.0% (−0.6 pts)2020: 24.5% (+0.6 pts)2021: 26.2% (+1.7 pts)2022: 26.2% (−0.0 pts)2023: 27.4% (+1.3 pts)2024: 26.9% (−0.6 pts)2025: 28.2% (+1.4 pts)
20162025

ZTS revenue and net income

RevenueNet incomeNet margin (right axis)

Where ZTS's revenue goes

2025
Revenue
$9.47B100.0%
Cost of revenue
−$2.79B−29.5%
Gross profit
$6.67B70.5%
Research & development
−$698.0M−7.4%
Sales, general & admin
−$2.38B−25.1%
Operating income
$3.60B38.0%
Interest & other expense
−$237.0M−2.5%
Income taxes
−$687.0M−7.3%
Net income
$2.67B28.2%

Each bar shows an amount and its share of revenue. ZTS kept 28.2% of revenue as net income.

ZTS profit margins

GrossOperatingNet

ZTS growth rates

to 2025
1 year3 years5 years10 years
Revenue+2.3%+5.4%+7.2%+7.1%
Gross profit+4.3%+6.8%+8.4%+8.4%
Operating income+6.0%+7.1%+9.7%+12.8%
Net income+7.5%+8.1%+10.3%+22.9%
EPS (diluted)+8.4%+9.6%+10.8%+13.8%

1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.

ZTS quarterly EPS vs estimates

Reported EPSAnalyst estimate

Zoetis beat the analyst EPS estimate in 7 of the last 8 quarters. Next report: November 5, 2026 (estimate $1.51).

ZTS income statement

Zoetis Inc. annual income statement
2025202420232022202120202019201820172016
Revenue$9.47B$9.26B$8.54B$8.08B$7.78B$6.67B$6.26B$5.83B$5.31B$4.89B
Cost of revenue$2.79B$2.86B$2.71B$2.60B$2.46B$2.22B$2.15B$2.03B$1.86B$1.75B
Gross profit$6.67B$6.40B$5.83B$5.48B$5.31B$4.46B$4.11B$3.80B$3.44B$3.14B
Research & development$698.0M$686.0M$614.0M$539.0M$508.0M$463.0M$457.0M$432.0M$382.0M$376.0M
Sales, general & admin$2.38B$2.32B$2.15B$2.01B$2.00B$1.73B$1.64B$1.48B$1.32B$1.32B
Total operating expenses$3.08B$3.00B$2.77B$2.55B$2.51B$2.19B$2.10B$1.92B$1.72B$1.74B
Operating income$3.60B$3.39B$3.07B$2.93B$2.80B$2.27B$2.02B$1.88B$1.73B$1.40B
Interest income$93.0M$106.0M$105.0M$50.0M$6.0M$12.0M$37.0M$31.0M——
Interest expense$243.0M$242.0M$258.0M$237.0M$236.0M$249.0M$242.0M$212.0M$175.0M$166.0M
Income before taxes$3.36B$3.13B$2.94B$2.66B$2.49B$2.00B$1.80B$1.69B$1.52B$1.23B
Income taxes$687.0M$637.0M$596.0M$545.0M$454.0M$360.0M$301.0M$266.0M$663.0M$409.0M
Net income$2.67B$2.49B$2.34B$2.11B$2.04B$1.64B$1.50B$1.43B$864.0M$821.0M
EBITDA$4.07B$3.87B$3.69B$3.36B$3.17B$2.69B$2.46B$2.21B$1.94B$1.63B
EPS (diluted)$6.42$5.92$5.32$4.88$4.70$3.85$3.64$3.14$2.40$1.96
Gross margin70.5%69.1%68.3%67.8%68.3%66.8%65.7%65.2%64.9%64.3%
Operating margin38.0%36.6%35.9%36.2%36.0%34.0%32.2%32.3%32.5%28.7%
Net margin28.2%26.9%27.4%26.2%26.2%24.5%24.0%24.5%16.3%16.8%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ZTS's financial statements (latest annual report filed February 12, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.

ZTS financial results

In fiscal year 2025 (ended December 31, 2025), Zoetis reported revenue of $9.5 billion, up 2.3% from the year before. It had net income of $2.7 billion (up 7.5%), a net profit margin of 28.2%. Diluted earnings per share came to $6.42. Over five years revenue grew at an average rate of 7.2% a year.

See the ZTS stock overview for the latest quote and news, or the ZTS chart for price history and technical indicators.

ZTS income statement FAQ

What is Zoetis's annual revenue?

Zoetis reported total revenue of $9.5 billion for fiscal year 2025, which ended on December 31, 2025. That was up 2.3% from $9.3 billion the previous year.

Is Zoetis profitable?

Yes. Zoetis reported net income of $2.7 billion in fiscal 2025, a net profit margin of 28.2%; its operating margin was 38.0%.

What is Zoetis's gross margin?

Zoetis's gross margin was 70.5% in fiscal 2025: for every $100 of revenue, Zoetis kept $70 after the direct cost of its products and services.

How much does Zoetis spend on research and development?

Zoetis spent $698.0 million on research and development in fiscal 2025, 7.4% of revenue.

How fast is Zoetis growing?

Revenue grew 7.2% a year on average over the last five fiscal years, from $6.7 billion to $9.5 billion.

What are Zoetis's earnings per share?

Zoetis earned $6.42 per diluted share in fiscal 2025, compared with $5.92 a year earlier.

When will Zoetis report its next earnings?

Zoetis is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens.

When does Zoetis's fiscal year end?

Zoetis's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 12, 2026.

Drug Manufacturers - Specialty & Generic income statements